Thrombopoietin is encoded by the THPO gene and consists of 353 amino acids. The recombinant form of human thrombopoietin, often produced in HEK293 cells, includes a His-tag (a sequence of histidine residues) at the C-terminus. This His-tag facilitates the purification process through affinity chromatography .
Recombinant human thrombopoietin (rhTPO) has been extensively studied for its ability to stimulate megakaryocyte growth and platelet production. It is biologically active in reducing thrombocytopenia (a condition characterized by low platelet counts) induced by nonmyeloablative chemotherapy . However, its benefits in stem cell transplantation or leukemia chemotherapy have not been demonstrated .
Thrombopoietin has been investigated for various clinical applications, including:
Ongoing and future studies aim to further define the clinical role of recombinant TPO and TPO mimetics in the treatment of various forms of thrombocytopenia. Researchers are also exploring its potential in ex vivo expansion of pluripotent stem cells and as a radioprotectant .
In summary, Thrombopoietin (Human Recombinant, His Tag) is a vital protein with significant potential in clinical applications related to platelet production and thrombocytopenia management. Its recombinant form, enhanced with a His-tag, allows for efficient production and purification, making it a valuable tool in both research and therapeutic settings.